Cognitive functions of patients treated with chemotherapy: A comparative study

Objectives. - Chemobrain is a well-established clinical syndrome that has become an increasing concern because of the growing number of long-term cancer survivors. It refers to the post-chemotherapy related cognitive dysfunction. The aim of this study was to objectively assess the impact of cancer treatment on the cognition of cancer patients. Methods. - This was a convenience sample comparative study conducted at the Hematology and Oncology Department of H & ocirc;tel Dieu de France University Hospital in Beirut, Lebanon. It included cancer patients (G1) aged under 65 years who had already been treated for cancer compared to two control groups. The first control group (G2) consisted of treatment-naive cancer patients aged under 65, and the second group (G3) was recruited from a pool of healthy controls aged between 40 and 65 years. All participants were asked to complete the part B of the trail making test (TMT) and the digital symbolic substitution test (DSST). Results. - In the bivariate analysis, patients in G1 had significantly higher scores than patients in G2 (P = 0.017) and G3 (P < 0.001) on the TMT-B. However, patients in G1 only had lower scores on DSST when compared with G3 (P = 0.017). In the logistic regression taking different groups two-by-two as the dependent variable, the only significant difference was found in the comparison between G2 and G3 with higher TMT-B scores more in favor of belonging to G2 (OR = 0.946; P = 0.003). Conclusions. - Our results suggest that, after controlling for anxiety and depression symptoms, patients treated with chemotherapy have significantly poorer outcomes on the DSST and TMT-B than treatment- na & iuml;ve cancer patients and healthy controls. However, when taking confounding factors into account, the difference only persisted between patients undergoing chemotherapy and healthy controls. These findings are in favor of a multifactor cognitive impairment in patients with cancer partially related to chemotherapeutic treatment. (c) 2023 L'Encephale, Paris.